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ABSTRACT 1 
1α,25-Dihydroxyvitamin D3 (1,25(OH)2D3) and other vitamin D compounds are promising 2 
molecules in the prevention and therapy of colon cancer and other neoplasias. To study the 3 
mechanism of action of 1,25(OH)2D3 in colon cancer cells, we carried out a comparative 4 
proteomic analysis of the nuclear fractions of SW480-ADH cells treated with 1,25(OH)2D3 5 
or vehicle during 8 or 48h. 2D-DIGE analysis combined with MALDI-TOF-TOF mass 6 
spectrometry interrogation led to the identification of 59 differentially-expressed unique 7 
proteins. Most identified proteins were nuclear, but several cytoskeleton-associated 8 
proteins were also detected. A good concordance between changes in expression at protein 9 
and RNA levels was observed for the validated proteins. A large group of identified 10 
proteins, such as SFPQ, SMARCE, KHSRP, TARDBP and PARP1, were involved in RNA 11 
processing or modification and have been ascribed to the spliceosome compartment of 12 
human cells. In addition, a smaller group of proteins (ERM (Ezrin, Radixin, Moesin) 13 
family, VCL, CORO1C, ACTB) were cytoskeleton-associated and played a role in cell 14 
adhesion and morphology. These results confirm the induction of epithelial phenotype by 15 
1,25(OH)2D3 and suggest a role for vitamin D compounds in the regulation of the 16 
spliceosome and thus, in alternative splicing and possibly microRNA synthesis in colon 17 
cancer cells. 18 
 19 
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INTRODUCTION 1 
Many epidemiological studies have shown an inverse relation between exposure to 2 
sunlight, vitamin D3 (cholecalciferol) intake or 25-hidroxyvitamin D3 (calcidiol) blood 3 
levels and the incidence of several neoplasias, particularly colorectal cancer (CRC) [1-4]. 4 
Preclinical data obtained in cultured cells and experimental animals support a protective 5 
effect of vitamin D compounds (vitamin D3, its most active metabolite 1α,25-6 
dihydroxyvitamin D3 (calcitriol), or less calcemic derivatives) against a variety of cancers 7 
[5-7]. Clinical trials have been scarce and inconclusive [7-9], and several are in progress 8 
using different vitamin D compounds alone or in combination in patients with different 9 
neoplasms (see ClinicalTrials.gov). 10 
 1α,25-Dihydroxyvitamin D3 (1,25(OH)2D3) has anti-proliferative, pro-apoptotic and 11 
pro-differentiation effects on many tumor cell lines. In human SW480-ADH colon cancer 12 
cells that express vitamin D receptor (VDR), 1,25(OH)2D3 induces CDH1/E-cadherin 13 
expression, an epithelial differentiated adhesive phenotype and antagonizes the Wnt/ -14 
catenin signaling pathway [10]. A global transcriptomic study showed that 1,25(OH)2D3 15 
changes significantly the RNA expression profile of these cells: about two-thirds of the 16 
target RNAs were upregulated and one-third were downregulated [11]. These RNAs 17 
encoded for proteins involved in many different cell functions including transcription, cell 18 
adhesion, DNA synthesis, apoptosis, redox status and intracellular signaling. In-depth 19 
functional studies of some of the reported target genes such as DICKKOPF-1, 20 
CST5/Cystatin D or SPROUTY-2 confirmed their role mediating the protective effect of 21 
1,25(OH)2D3 against colon cancer [12-14]. 22 
 Several transcriptomic studies searching for RNAs regulated by 1,25(OH)2D3 have 23 
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been done in different cell types [11, 15-17]. However, studies at the protein level in 1 
human cancer cells are lacking. In order to get a more comprehensive understanding of the 2 
molecular mechanisms of action of 1,25(OH)2D3 we have used 2D-DIGE electrophoresis 3 
combined with MALDI-TOF-TOF mass spectrometry to identify proteins regulated by 4 
1,25(OH)2D3 in SW480-ADH cells. We used nuclear extracts from 1,25(OH)2D3- and 5 
vehicle-treated cells based on the results of previous transcriptomic studies, which showed 6 
that 1,25(OH)2D3 regulates many transcription factors and other nuclear proteins [11]. 7 
Moreover, the wide gene regulatory effects of 1,25(OH)2D3 cannot be exclusively 8 
mediated by VDR binding to their promoters and should require additional changes in 9 
transcription regulators. Finally, the pre-fractionation of the cellular content should 10 
facilitate the identification of non-abundant proteins by decreasing those of preferential 11 
cytosolic and membrane location. Here, a number of novel 1,25(OH)2D3-regulated proteins 12 
were identified. Validation of candidate target proteins was performed by Western blot, 13 
immunofluorescence and quantitative PCR analyses. Interestingly, several 1,25(OH)2D3-14 
regulated proteins were related with the spliceosome compartment and RNA metabolism, 15 
suggesting a role of 1,25(OH)2D3 on alternative splicing, a process frequently altered in 16 
cancer cells [18-19]. 17 
18 
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MATERIALS & METHODS 1 
Cell culture 2 
SW480-ADH human colon cancer cells were grown in DMEM supplemented with 10% 3 
FCS (Invitrogen). The active vitamin D metabolite 1,25(OH)2D3 was used for cell 4 
treatment. Briefly, cells were washed twice with PBS and incubated with 100 nM 5 
1,25(OH)2D3 (with isopropanol as vehicle) in DMEM supplemented with liposoluble 6 
hormone-depleted FCS for the indicated times. 7 
 8 
Protein extraction and subcellular fractioning  9 
To obtain nuclear extracts, cell monolayers were washed in PBS and lysed for 15 min in 10 
hypotonic buffer (10 mM HEPES pH 7.5, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA) 11 
supplemented with 1 mM DDT, 1 mM ortovanadate, 1 mM PMSF, 10 mg/ml leupeptin 12 
and 10 mg/ml aprotinin. Just before centrifugation (13,000 rpm at 4°C for 1 min), 10% 13 
NP40 was added to the tubes. Supernatants (cytosolic extracts) were conserved at -80°C 14 
until analysis. Pellets containing nuclei were lysed by incubation for 30 min in hypertonic 15 
buffer (20 mM HEPES pH 7.5, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA) supplemented as 16 
above, and then centrifuged at 13,000 rpm for 10 min at 4°C. Supernatants (nuclear 17 
extracts) were conserved at -80°C until analysis. Protein expression of cytosolic -Tubulin 18 
and Rho-GDI) and nuclear (HDAC, Lamin B and VDR) markers was assessed by Western 19 
blot to confirm a correct fractioning (Fig. 1A). 20 
 21 
2D-DIGE electrophoresis 22 
Nuclear extracts were precipitated using methanol/chloroform [20]. Briefly, samples were 23 
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incubated with 0.1% deoxycolic acid at 4°C for 10 min. Just before centrifugation (13,000 1 
rpm at 4°C for 30 min), cold methanol and chloroform were added to the sample tubes. 2 
Protein-interphase was washed and centrifuged twice with cold methanol. Pellets were 3 
dried and resuspended in 2D lysis buffer (7 M urea, 2 M thiourea, 30 mM Tris-HCl pH 8.5, 4 
4% CHAPS). 2D-DIGE experiments were carried out as previously described [21-23]. 5 
Briefly, after protein quantification with RC DC Protein Assay (Bio-Rad), 50 μg of each 6 
nuclear protein extract was DIGE labeled (CyDye DIGE Fluor, minimal labeling kit, GE 7 
Healthcare) with 400 pmol CyDyes on ice for 30 min and then blocked with L-Lysine for 8 
10 min (incubations were done in the dark on ice). Nuclear protein extracts from SW480-9 
ADH control and 1,25(OH)2D3-treated cells were labeled with Cy3 and Cy5 10 
fluorochromes, respectively. A pool containing equal amounts of extract from each cell 11 
condition was labeled with Cy2 dye and was included in all gel runs. First dimension was 12 
run on IPG strips (pH 3–10 NL, 18 cm length) (GE Healthcare) in a Multiprotean IEF cell 13 
(Bio-Rad) with a 7 steps program (50 V for 10 h, 100 V for 1 h, 250 V for 1 h, 500 V for 1 14 
h, 1000 V for 1 h, 8000 V for 1 h and 8000 V until voltage reached 50 kVh). Second 15 
dimension was run overnight on 11% SDS-PAGE in a cooled Protean Plus Dodeca (Bio-16 
Rad). Samples were run for 1 h more after the dye-front run out of the gel. Protein 17 
expression patterns were visualized with a Typhoon 9400 scanner (GE Healthcare). Images 18 
were processed using two different softwares for analysis: Redfin Analysis Center-Pro 19 
(Ludesi) and Progenesis Samespots (NonLynear Dymanics). Cy3:Cy2 and Cy5:Cy2 ratios 20 
for each individual protein were used for quantification. After quantification and 21 
normalization of spots, statistical analysis was applied to find significant differences 22 
between groups of samples. The 12 spot maps corresponding to 4 replica gels/treatment 23 
were used to calculate average abundance changes and paired ANOVA p-values and fold-24 
7 
 
change for each protein across the different gels. Protein spots that showed a significant 1 
change in abundance between control and treatment (ANOVA-test p<0.05; fold-change 2 
>1.25 or <0.80) were selected for further characterization by mass spectrometry. 3 
 4 
Identification of proteins by MALDI-TOF-TOF peptide mass fingerprinting 5 
A preparative gel containing 500 μg of each nuclear extract was run and stained with the 6 
Colloidal Blue Staining Kit (Invitrogen) for protein visualization and spot picking after 7 
matching against the analytical gels. Spots of interest were automatically excised using a 8 
ProteomeWorks Spot Cutter (Bio-Rad) and subjected to manual tryptic digestion. For 9 
digestion, gel pieces were washed first with 50 mM ammonium bicarbonate (Sigma-10 
Aldrich) and second with ACN (Scharlau). Trypsin (Promega), at a final concentration of 11 
12.5 ng/μl in 50 mM ammonium bicarbonate solution, was added to the gel pieces for 8 h 12 
at 37 ºC. Finally, 70% ACN containing 0.5% TFA (Sigma-Aldrich) was added for peptide 13 
extraction. Tryptic eluted peptides were dried by speed-vacuum centrifugation and 14 
resuspended in 4 μl of 30% ACN - 0.1% TFA. One µl of each peptide mixture was 15 
deposited onto an 800 µm AnchorChip (Bruker-Daltonics) and dried at RT. One µl of 16 
matrix solution (3 mg/ml α-cyano-4-hydroxycinnamic acid) in 33% ACN - 0.1% TFA was 17 
then deposited onto the digest and allowed to dry at room temperature. 18 
 Samples were analyzed with an Autoflex III TOF/TOF mass spectrometer (Bruker-19 
Daltonics). Typically, 1000 scans for peptide mass fingerprinting (PMF) and 2000 scans 20 
for MS/MS were collected. Automated analysis of mass data was performed using 21 
FlexAnalysis software (Bruker-Daltonics). Internal calibration of MALDI-TOF mass 22 
spectra was performed using two trypsin autolysis ions with m/z 842.510 and m/z 23 
2211.105; for MALDI-MS/MS, calibrations were performed with fragment ion spectra 24 
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obtained for the proton adducts of a peptide mixture covering the m/z 800–3200 region. 1 
The typical error observed in mass accuracy for calibration was usually below 20 ppm. We 2 
verified this accuracy intra-experiment with ACTB peptides. MALDI-MS and MS/MS 3 
data were combined through the BioTools 3.0 program (Bruker-Daltonics) to interrogate 4 
the NCBI non-redundant protein database (NCBI: 20100306) using MASCOT software 5 
v2.3 (Matrix Science). Relevant search parameters were set as follows: enzyme, trypsin; 6 
fixed modifications, carbamidomethyl (C); oxidation (M); 1 missed cleavage allowed; 7 
peptide tolerance, 20 ppm; MS/MS tolerance, 0.5 Da. Protein scores greater than 75 were 8 
considered significant (p<0.05). 9 
 10 
Western blot 11 
Nuclear protein extracts were separated by SDS-PAGE electrophoresis and transferred to 12 
Transblot nitrocellulose membranes (Bio-Rad). Membranes were incubated with the 13 
appropriate primary and secondary horseradish peroxidase-conjugated (Sigma-Aldrich) or 14 
fluorescence Alexa-conjugated (Invitrogen) antibodies. The antibody binding was 15 
visualized using SuperSignal Substrate (Pierce) or ECL Western Blot Detection Reagents 16 
(GE Healthcare) with a fluorescent image analyzer FLA-3000 (Fuji Photo Film Co. Ltd.). 17 
The following primary antibodies were used: LMNB, PARP1, NCL, HDAC, Rho-GDI 18 
(Santa Cruz Biotechnology); SFPQ, KHSRP (Abnova Corporation); PPIA, VDR 19 
(Millipore); TARDBP, RBBP4, NPM1, PHB (Abcam), -Tubulin (Sigma-Aldrich). EZR 20 
and SMARCE1 antibodies were kindly provided by Dr JM Serrador (Centro Nacional de 21 
Investigaciones Cardiovasculares, Madrid) and Dr B Belandia (Instituto de Investigaciones 22 
Biomédicas “Alberto Sols”, Madrid), respectively. Quantification was done by 23 
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densitometry using Quantity One software (Bio-Rad) and LMNB was used as a loading 1 
control.  2 
 3 
Immunofluorescence and confocal microscopy 4 
Cells were rinsed once with PBS, fixed in 4% paraformaldehyde for 10 min at RT and 5 
rinsed twice with PBS. Afterward, cells were permeabilized with 0.2% Triton X-100 for 10 6 
min and then washed three times with PBS. Non-specific sites were blocked with 5% BSA 7 
in PBS for 1 h at RT. Then, cells were incubated with primary antibodies diluted in PBS-8 
5% BSA for 1 h at 37°C in a humidity chamber. After three washes in PBS, cells were 9 
incubated with Alexa-conjugated antibodies diluted 1/250 for 1 h at 37°C, and then washed 10 
three times with PBS. Finally, cells were mounted in fluorescent media (Dako). Confocal 11 
microscopy was performed with a TCS SP5 laser scanning microscope (Leica), using a 63x 12 
oil objective (2x zoom) and excitation at 488/633 nm to detect Alexa 488 or Alexa 647, 13 
respectively. We used primary antibodies against: EZR, KHSRP, NPM1, PARP1, RBBP4, 14 
SFPQ, SMARCE1, TARDBP (same as for Western blot), NCL (Abcam) and CDH1/E-15 
cadherin (BD Biosciences). Anti-rabbit Texas Red-conjugated was used for NCL as 16 
secondary antibody. 17 
 18 
RNA extraction and quantitative RT-PCR 19 
RNA was extracted from cultured cells using RNeasy Mini Kit (Qiagen) and 20 
retrotranscribed using the High-Capacity cDNA Archive Kit (Applied Biosystems). Target 21 
genes RNA expression was measured by quantitative RT-PCR in relation to that of 18S 22 
rRNA applying the comparative CT method [24] and using RNA TaqMan probes (Applied 23 
Biosystems) for KHSRP, PARP1 and SFPQ or oligonucleotides for SMARCE1 (sense 5’-24 
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GTCGGTTGTCACAACAGCTAGAA-3’, antisense 5’-TCTAGTTTCCGCTGATGAACCA-1 
3’) and CDH1/E-cadherin (sense 5’-AGAACGCATTGCCACATACACTC-3’, antisense 2 
5’-CATTCTGATCGGTTACCGTGATC-3’). The quantitative PCR reaction was performed in 3 
an ABI Prism 7900 HT thermal cycler using TaqMan or SYBR Gene Expression Master 4 
Mix (both from Applied Biosystems). Thermal cycling consisted of a denaturing step at 5 
95ºC for 10 min and 40 cycles of denaturing at 95ºC for 15 s and annealing and elongation 6 
at 60ºC for 60 s. Statistical significance was assessed by two-tailed unpaired Student´s t-test 7 
(* p 0.05, ** p 0.01, *** p 0.001). 8 
 9 
Bioinformatic analysis  10 
GO-term analysis and functional annotation was carried out with DAVID [25]. DAVID 11 
uses a modified Fisher Exact p-value to determine whether a GO-term is over- or under-12 
represented in a given proteomic data set. Enrichment scores denote the geometric mean of 13 
all the enrichment p-values for each annotation term associated with the gene members in 14 
the group [26]. Enrichment scores above 1.3 were statistically significant (1.3 is equivalent 15 
to p-value < 0.05). Protein interaction analysis was carried out with the free web-based tool 16 
STRING [27]. STRING is a database of known and predicted protein interactions. We 17 
used iHOP [28] for text mining and KEGG for pathway studies [29]. Moreover, individual 18 
characteristics of the identified proteins (location, function, etc) were assigned or 19 
confirmed using bioinformatic tools like GeneCards (www.genecards.org). All these 20 
resources are freely available for academic users. 21 
22 
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RESULTS 1 
Identification of proteins regulated by 1,25(OH)2D3 using 2D-DIGE analysis 2 
Nuclear extracts from SW480-ADH cells treated with 1,25(OH)2D3 or vehicle for 8 or 48 h 3 
were analyzed by 2D-DIGE, for early and late events, respectively. These time points were 4 
selected to discriminate between E-cadherin-dependent or -independent 1,25(OH)2D3 5 
target genes, as CDH1/E-cadherin protein increases 10-12 h after 1,25(OH)2D3 treatment 6 
and is responsible for a drastic morphological change in SW480-ADH cells [10]. Also, 7 
they may permit to differentiate between direct and indirect 1,25(OH)2D3 targets. Changes 8 
in the pattern of protein expression were quantitatively and statistically analyzed by using 9 
Ludesi Redfin and Progenesis Samespots considering the 12 spot-maps included in the 10 
study for each time point. Each gel was analyzed individually to calculate the volume 11 
ratios between individual samples and the internal pool, which was used as the standard 12 
reference. Then, all the images were combined and analyzed together by using both 13 
softwares. 115 spots differentially-expressed between 1,25(OH)2D3- and vehicle-treated 14 
cells were selected based on the fold-change (<0.80 or >1.25) and the ANOVA p-value 15 
(<0.05). The spots of interest were picked from a preparative gel for protein identification. 16 
Using this strategy 59 differentially-expressed unique proteins were identified in nuclear 17 
extracts from 1,25(OH)2D3-treated SW480-ADH cells (Tables 1a and 1b). In addition, a 18 
number of proteins was identified as different isoforms or fragments (ACTB (4), PP1A (4), 19 
EZR (3), XRCC6 (2), YWHAE (2), SMARCE1 (2), ATP5A1 (2), PHB (2), being the 20 
number of isoforms or fragments shown among parentheses), which raised the total 21 
number of identifications to 72. At 8 h, only 12 changes in protein abundance were 22 
observed between 1,25(OH)2D3-treated and control cells, all of them downregulated 23 
(Supplementary information Fig. 1, Table 1a); whereas 47 protein changes were found at 24 
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48 h treatment (Fig. 1B, Table 1b). 1,25(OH)2D3 might act primarily as repressing 1 
gene/protein expression because nuclear VDR binds to the promoter of their target genes, 2 
recruits transcriptional co-repressors and so inhibits gene expression. Then, 1,25(OH)2D3 3 
increases VDR DNA binding and induces the replacement of VDR-bound co-repressors by 4 
transcriptional co-activators, altogether favouring gene induction. This may explain, at 5 
least in part, why the percentage of induced genes augments with time after 1,25(OH)2D3 6 
treatment. 7 
 Downregulated proteins included SFPQ, SMARCE1, RBBP4, RBBP7, G3BP1, and 8 
various members of 14-3-3 protein family (YWHAE, YWHAG, YWHAQ). However, 9 
some proteins implicated in epithelial morphology and cell adhesion (ERM (Ezrin, 10 
Radixin, Moesin) family, VCL, ACTB, KRT8) were increased by 1,25(OH)2D3. Other 11 
proteins whose levels were upregulated were TARDBP, KHSRP and LMNA. A substantial 12 
number of identified proteins such as SFPQ, SMARCE, KHSRP, TARDBP and PARP1, 13 
among others, were involved in RNA maturation (splicing, modification) as constituents of 14 
the spliceosome and show predominant nucleolar location. Other proteins, such as EZR, 15 
although having a major role in cell adhesion or morphology and being mainly described 16 
as cytosolic, membrane or cytoskeletal proteins, have also been found to be partially 17 
nuclear [30]. 18 
 19 
Correlation between alterations at the protein and RNA level 20 
Nuclear extracts of SW480-ADH cells treated with 1,25(OH)2D3 or vehicle for 8 or 48 h 21 
were analyzed by Western blot using specific antibodies against a panel of altered proteins 22 
(Fig. 2). Three independent experiments were done. We confirmed that the nuclear content 23 
of NCL, EZR, KHSRP and TARDBP increased by 1,25(OH)2D3 treatment. By contrast, 24 
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the levels of RBBP4, SFPQ, NPM1, PARP1, PHB, SMARCE1 and PPIA were lower in 1 
the nuclear extracts of 1,25(OH)2D3-treated cells than in control cells. Ratios of expression 2 
between 1,25(OH)2D3- and vehicle-treated cells were similar to those found by 2D-DIGE. 3 
Furthermore, we selected a few proteins to study whether the changes in their 4 
protein expression correlated with alterations at the RNA level. This was the case for all 5 
four cases studied: similarly to protein levels, the RNA expression of PARP1, SMARCE1 6 
and SFPQ decreased by 1,25(OH)2D3 treatment and those of KHSRP were induced (Fig. 7 
3). These results suggest a transcriptional regulation of these genes. As a positive control, 8 
we confirmed the induction by 1,25(OH)2D3 of CDH1/E-cadherin RNA expression, a well 9 
known 1,25(OH)2D3 target gene [10, 31]. To further study the correlation between 10 
alterations at the protein and RNA and level, we compared the results of the proteomic 11 
study with those of our own transcriptomic analyses [11 and unpublished results]. This 12 
analysis revealed that only 13 out of the 57 proteins were found as regulated by 13 
1,25(OH)2D3 in SW480-ADH cells in both types of studies (Table 2). In all these cases, 14 
regulation followed the same trend. 15 
 16 
Validation of differentially-regulated proteins by immunofluorescence analysis 17 
Immunofluorescence and confocal microscopy analysis of cells treated with 1,25(OH)2D3 18 
or vehicle was used to further confirm the regulation and to examine the subcellular 19 
location of the identified proteins (Fig. 4). A good correlation was observed with the 20 
Western blot analyses. NCL pattern of expression was similar in vehicle- or treated-cells, 21 
strong signal in nucleolus and diffuse in nucleoplasm, but more intense in 1,25(OH)2D3-22 
treated cells. TARDBP and KHSRP levels were higher in both nucleus and cytosol in 23 
SW480-ADH treated with 1,25(OH)2D3, showing a punctuate pattern with a few defined 24 
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nuclear foci. In contrast, and in agreement with Western blot data, RBBP4, SFPQ, PARP1, 1 
NPM1 and SMARCE1 expression was lower in 1,25(OH)2D3-treated SW480-ADH cells 2 
than in vehicle-treated cells. For RBBP4, SFPQ and PARP1, the expression was 3 
exclusively nuclear; whereas NPM1 and SMARCE1 were located at both the nucleus and 4 
cytoplasm. As expected, EZR was preferentially located close to the plasma membrane and 5 
its expression was higher in 1,25(OH)2D3-treated cells (Fig. 4). 6 
 7 
Cellular localization and biological function of 1,25(OH)2D3-regulated proteins 8 
Gene ontology and functional classification of the identified proteins was carried out with 9 
DAVID bioinformatics tools [26]. Molecular function of the identified proteins according 10 
to GO ontology is represented in Fig. 5A. There was a predominant enrichment in 11 
functional terms like RNA and nucleotide binding, RNA processing, telomeric DNA 12 
binding, cytoskeleton organization, cell adhesion and protein kinase binding. These terms 13 
should indicate the biological functions where 1,25(OH)2D3 treatment exert its effects. In 14 
particular, there was enrichment in nuclear proteins (enrichment factor: 6.55, 15 
Supplementary information Fig. 2A). Some of these proteins were previously identified as 16 
nucleolar [32]. By functional annotation clustering, one of the main groups was related to 17 
RNA binding and processing (enrichment factor: 2) (Fig. 5B). This group includes 17 18 
proteins, either up- or down-regulated, which stresses the relevance of 1,25(OH)2D3/VDR 19 
as a regulator of RNA maturation and RNA metabolism/editing. Proteins as KHSRP, 20 
TARDBP or SFPQ work as splicing factors and participate in the formation of the 21 
spliceosome [33-34]. Ribosomal proteins (RPLP2, RPSA, MRPS23), ATPases (ATP5B), 22 
helicases (XRCC6), PARP1 and chaperones (HSPA9) are also common components of the 23 
nucleolar fraction and many of them have also been reported as components of the 24 
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proteome of spliceosomes assembled in vitro [35]. In addition, it has recently been 1 
described the ability of PARP1 to modulate the splicing process [36]. 2 
 Another functional group was composed by proteins related with cytoskeleton 3 
organization, actin binding and cell adhesion (LMNA, VCL, SEPT2, KRT8, KRT9, 4 
ACTB, ERM family) (enrichment score: 1.96, Supplementary information Fig. 2B).  5 
 6 
Alterations in the spliceosome compartment and cellular adhesion proteins in 7 
1,25(OH)2D3-treated colon cancer cells  8 
Proteins identified as 1,25(OH)2D3 targets were classified and clustered using several 9 
algorithms. STRING was used to find interaction groups. In order to expand the initial 10 
interaction network, STRING added 10 more partners. By means of MCL algorithm, two 11 
major clusters of interacting proteins were highlighted by STRING (Fig. 6). A large cluster 12 
corresponded to proteins previously identified as spliceosome components [35]. Within 13 
this group were TARDBP, KHSRP, SFPQ and the family of DNA-directed RNA 14 
polymerases I, II, and III, which synthesize ribosomal RNA precursors, mRNA precursors 15 
and a large number of non-coding RNAs and small RNAs, respectively. The presence of 16 
RNA polymerase II and other transcription factors in the spliceosome was previously 17 
described [35], suggesting a tight coupling of transcription with splicing [37]. 18 
 Up-regulated KHSRP is a well-known regulator of splicing, among its targets being 19 
the c-SRC proto-oncogene [38]. KHSRP plays also a role in the processing of microRNAs 20 
as a component of both Drosha and Dicer complexes and regulates the biogenesis and 21 
maturation of a subset of miRNAs [39]. Additionally, KHSRP interacts with single-strand 22 
AU-rich-element-containing mRNAs and is a key mediator of mRNA decay [40]. It targets 23 
the expression of mRNAs that affect specific biological programs, including proliferation, 24 
16 
 
apoptosis and differentiation. TARDBP is also up-regulated by 1,25(OH)2D3, it displays a 1 
similar functionality to KHSRP in the regulation of microRNAs, i.e. let7b [41]. Other 2 
interaction platforms (iHOP) showed interactions between TARDBP and TMLHE and 3 
RNA polymerases I, II, and III.  4 
 According to the text-mining program iHOP (data not shown), LMNA, CORO1C, 5 
XRCC6 or NCL proteins act as a hub to interconnect other proteins such as NPM1, 6 
PPP1CB, EEF1G or RBBP7. RBBP4 interacts with HDAC1 and both mediate chromatin 7 
remodeling and transcription regulation. In line with this, a recent genome-wide analysis of 8 
VDR binding sites has shown a significant enrichment of sites in regions associated with 9 
active chromatin such as DNase I-hypersensitive sites and regions with specific histone 10 
modifications [42]. Another interaction node was centered on NCL and PPP1CB (protein 11 
phosphatase 1, beta isoform), which might cooperate to downregulate NPM1 and HMGB2 12 
that are involved in cell proliferation. A few small groups including elongation factors, 13 
mitochondrial proteins and the 14-3-3 protein family were also observed (Fig. 6). 14 
 A second cluster was composed of cytoskeleton-associated proteins (ERM family, 15 
VCL, ACTB, CORO1C, PPP1CB (also known as MLCP) and IQGAP3) (Fig. 6). KEGG 16 
pathways analysis showed that increases in the abundance of ERM family, VCL and 17 
ACTB contribute to the increase of focal adhesions in 1,25(OH)2D3-treated cells and, 18 
therefore, to cell-matrix adhesion [43] (Supplementary information Fig. 3). It also 19 
suggested the involvement of phosphatidylinositol-5-phosphate 4-kinase type II β 20 
(PI4P5K) and phosphatidylinositol-4,5-bisphosphate (PIP2) signalling in VCL and ACTB 21 
expression and focal adhesion assembly. Accordingly, PI4P5K has been recently 22 
implicated in the induction of E-cadherin and the inhibition of cell motility by 23 
1,25(OH)2D3 in colon cancer cells [44]. A decrease in IQGAP3 expression should increase 24 
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the adherens junctions and cell-cell contacts in the treated cells. Collectively, these data 1 
support the observations that 1,25(OH)2D3 modulates cell morphology through the RhoA-2 
ROCK pathway [31]. An increase of PPP1CB phosphatase could reduce actomyosin 3 
assembly contraction. Interestingly, PPP1 phosphatases have also been located in the 4 
nucleolus and are rapidly exchanging between the nucleolar, nucleoplasmic and 5 
cytoplasmic compartments [45]. Likewise, regarding down-regulation of CORO1C by 6 
1,25(OH)2D3, is worth mentioning that CORO1C-depleted cells have been reported to 7 
display increased cell-matrix adhesion and enhanced cell spreading [46]. These findings 8 
related to epithelial markers are in agreement with the observed effect of 1,25(OH)2D3 and 9 
several derivatives regulating the morphology and phenotype of colon carcinoma cells [10, 10 
31]. 11 
12 
18 
 
DISCUSSION  1 
Vitamin D compounds are promising molecules for the prevention and possibly for the 2 
therapy of cancer. They have pleiotropic effects affecting many intracellular pathways and 3 
cell compartments. Although several transcriptomic studies have identified genes whose 4 
RNA expression respond to 1,25(OH)2D3 or derivatives, little was known about changes at 5 
the protein level in cancer cells. In this report we describe for the first time the proteomic 6 
alterations induced by 1,25(OH)2D3 in the nucleus of human colon cancer cells. 2D-DIGE 7 
quantitative analysis enabled the identification of a number of target proteins that were 8 
predominantly down-regulated by 1,25(OH)2D3, particularly after 8 h treatment. In 9 
contrast, previous transcriptomic studies revealed that two thirds of 1,25(OH)2D3-regulated 10 
RNAs were up-regulated and one third was down-regulated [11]. However, when we 11 
compared our transcriptomic and proteomic data, we recovered 13 proteins that were 12 
present in both analyses as regulated by 1,25(OH)2D3 and these proteins showed the same 13 
trend in regulation. The reasons for the apparent discrepancy between proteomic and 14 
transcriptomic data are unclear and, probably, multifactorial. Among other reasons, the 15 
differences might arise from comparing a transcriptomic profile, that was not genome-wide 16 
[11], with the more partial nuclear proteome regulated by the hormone. Also, a different 17 
post-translational regulation, alternative splicing or stability issues of the proteins could 18 
explain the differences between mRNA and protein levels. In addition, as 2D-DIGE 19 
analysis is biased towards the detection of relatively abundant proteins, it can be assumed 20 
that additional changes affecting low-level expressed proteins were not detected. The use 21 
of more powerful LC-MS systems could lead to a deeper insight into the regulatory effects 22 
of vitamin D compounds on the proteome. 23 
 Despite nuclear extracts were used in the study, only 27 out of 59 proteins were 24 
19 
 
pre-assigned to the nucleus (Table 1), while the remaining were preferentially cytosolic, 1 
cytoskeletal, mitochondrial or membrane proteins. Although we cannot discard a slight 2 
contamination of nuclear extracts with cytosolic proteins, the latter proteins may be 3 
partially or temporarily present in the nucleus due to chemical modifications and/or 4 
transport mechanisms induced by specific signals. Accordingly, nuclear localization has 5 
been described for classical cytoskeleton-associated proteins as actin, myosin, filamin A 6 
and coronin 2A. Among the proteins identified in our study, EZR, in addition to its well-7 
known location at the subcortical region linking actin filaments to the plasma membrane, 8 
has been reported to be present within the nucleus of osteosarcoma cells in a 9 
phosphorylated form [30]. 10 
 We are also interested in the regulation of the epithelial-mesenchymal transition in 11 
colon cancer by vitamin D analogues. SNAIL1 and SNAIL2/SLUG are transcriptional 12 
repressors that induce epithelial-mesenchymal transition by inhibiting the expression of E-13 
cadherin and other adhesion proteins [47-48], and that also repress VDR and inhibit 14 
1,25(OH)2D3 action [49-50]. A recent proteomic study allowed the identification of 15 
SNAIL1 target proteins in SW480-ADH cells [21]. Among others, two proteins involved 16 
in RNA processing and splicing, CPSF6 and SFPQ, were found to be upregulated. 17 
Interestingly, we have now found that SFPQ was downregulated in 1,25(OH)2D3-treated 18 
cells, opposite to its upregulation in SNAIL1-transfected cells [21], which agrees with the 19 
antagonism between SNAIL1 and VDR, and further supports the involvement of 20 
1,25(OH)2D3/VDR in RNA biology. Giving the opposite effects of 1,25(OH)2D3 and 21 
SNAIL1 on the phenotype of colon epithelial cells, it is tempting to speculate that the 22 
splicing regulators here identified might play a role in the control of the epithelial-23 
mesenchymal transition process. SFPQ is involved in some cancer-related gene 24 
20 
 
translocations [51], and it is located in paraspeckles, a subnuclear compartment for pre-1 
mRNA processing and retention [52]. Moreover, SFPQ was shown to interact with RAD51 2 
and XRCC2 proteins of the DNA repair complex and involved in the maintenance of 3 
chromosome integrity [53]. We have identified XRCC6 DNA helicase and PARP1 Poly 4 
(ADP-ribose) polymerase as 1,25(OH)2D3-regulated proteins, which together suggest a 5 
role for SFPQ also in DNA repair.  6 
 7 
Conclusions 8 
 Many of the proteins identified in this study correspond to the nucleolar 9 
compartment and have been assigned to the spliceosome machinery. Interestingly, a 10 
significant number (8) of the proteins identified as regulated by 1,25(OH)2D3 showed a 11 
variable number of isoforms, which might result from a differential splicing. Cell nucleolus 12 
plays important roles in ribosome subunit biogenesis, maturation of RNAs, spliceosomal 13 
machinery and the regulation of specific regulatory factors [32]. Alternative splicing is an 14 
important point of control of gene expression that may render proteins with distinct and 15 
sometimes opposite activity and is frequently altered in cancer cells [19]. Remarkably, in 16 
malignancies of the digestive tract including colon cancer both aberrant splice variants and 17 
altered expression of splice variants have been described [18]. Thus, the panel of target 18 
proteins here identified may constitute a good starting point for the characterization of the 19 
effect of vitamin D compounds on the spliceosome machinery, which may in turn be 20 
relevant to understand their anti-tumoral effects. 21 
22 
21 
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Table 1a. Proteins differentially-expressed in SW480-ADH cells after 8 h 1,25(OH)2D3-treatment  
SPOT 
UNIPROT 
AC # PROTEIN GENE SCORE 
COVERAGE 
(%) MW (Da) pI  p 
FOLD 
CHANGE LOCALIZATION 
19 Q09028 Histone-binding protein RBBP4 RBBP4 334 35 46,656 4.74 0.003 0.78 Nucleus 
1276 P14618  Pyruvate kinase isozymes M1/M2 PKM2 107 36 57,937 7.95 0.015 0.78 Cytosol 
93 Q969G3 
SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily E member 1 SMARCE1 252 20 46,649 4.85 0.024 0.78 Nucleus 
1776 P30040 Endoplasmic reticulum protein ERp29 ERP29 82 21 28,993 6.08 0.003 0.76 Endoplasmatic reticulum 
97 Q0QEN7 ATP synthase subunit beta ATP5B 100 26 48,113 4.95 0.023 0.69 
Mitochondrial inner 
membrane 
14 Q86VI3 Ras GTPase-activating-like protein IQGAP3 IQGAP3 80 18 184,699 7.34 0.019 0.66 Intracellular 
15 Q9ULV4 Coronin-1C CORO1C 108 12 53,249 6.65 0.003 0.64 Actin cytoskeleton 
1121 P25705 ATP synthase subunit alpha, mitochondrial ATP5A1 300 28 59,751 8.28 0.003 0.56 
Mitochondrion inner 
membrane 
1360 P35232 Prohibitin PHB 484 42 29,804 5.57 0.009 0.56 
Mitochondrion inner 
membrane, nucleoplasm 
52 P05387 60S acidic ribosomal protein P2 RPLP2 122 64 11,665 4.42 0.008 0.52 
Cytosolic large ribosomal 
subunit 
32 P13645 Keratin, type I cytoskeletal 10 KRT10 88 18 59,511 5.13 0.000 0.48 Intermediate filament 
1347 P09661 U2 small nuclear ribonucleoprotein A' SNRPA1 192 52 28,416 8.72 0.009 0.41 Nucleus 
 
 
Table 1b. Proteins differentially-expressed in SW480-ADH cells after 48 h 1,25(OH)2D3-treatment  
SPOT 
UNIPROT 
AC # 
PROTEIN GENE SCORE 
COVERAGE 
(%) 
MW (Da) pI p 
FOLD 
CHANGE LOCALIZATION 
283 P38646 Stress-70 protein, mitochondrial HSPA9 259 18 73,680 5.44 0.005 2.50 Mitochondrion 
642 Q5TCI8  Lamin A/C LMNA 141 23 55,762 6.55 0.003 1.73 Nuclear matrix 
127 P60709 Actin, cytoplasmic 1 ACTB 103 27 41,137 5.29 0.003 1.72 Cytoskeleton 
561 P19338 Nucleolin NCL 121 22 76,614 4.60 0.001 1.71 Nucleus 
625 P15311 Ezrin, Moesin, Radixin, Cytovillin 2 
EZR / MSN / 
RDX / VIL2 
98,79,74,71 16 69,413 5.95 0.002 1.63 Cytoskeleton, cell membrane 
627 P15311 Ezrin EZR 182 29 69,413 5.95 0.001 1.61 Cytoskeleton, cell membrane 
802 P18206 Vinculin VCL 82 11 123,779 5.51 0.035 1.55 Cell membrane 
1349 P05787 Keratin, type II cytoskeletal 8 KRT8 119 28 53,704 5.52 0.030 1.55 Intermediate filament 
28 
 
907 Q92945 Far upstream element-binding protein 2 KHSRP 187 33 73,146 6.84 0.017 1.53 Nucleus 
516 P62140 
Serine/threonine-protein phosphatase PP1-beta 
catalytic subunit 
PPP1CB 117 23 37,187 5.85 0.003 1.52 Cytoplasm 
1154 P12956 ATP-dependent DNA helicase 2 subunit 1 XRCC6 206 17 69,843 6.23 0.015 1.46 Nucleus 
493 Q13148 TAR DNA-binding protein 43 TARDBP 83 4 44,740 5.85 0.042 1.44 Nucleus 
1086 Q9NVH6 Trimethyllysine dioxygenase, mitochondrial TMLHE 74 32 49,518 7.64 0.016 1.42 Mitochondrion 
1319 P51991 Heterogeneous nuclear ribonucleoprotein A3 HNRNPA3 193 21 39,595 9.10 0.026 1.39 Nucleus 
688 Q15019 Septin-2 SEPT2 460 38 41,487 6.15 0.039 1.38 Nucleus 
1746 P09661 U2 small nuclear ribonucleoprotein A' SNRPA1 120 39 28416 8.72 0.0008 0.79 Nucleus 
163 P25705 ATP synthase subunit alpha, mitochondrial ATP5A1 112 23 59751 8.28 0.028 0.76 Nucleus 
1074 Q9BSV4 SFPQ protein  SFPQ 143 23 68,631 8.89 0.019 0.75 Nucleus 
1797 P26583 High mobility group protein B2 HMGB2 103 39 24,034 9.45 0.043 0.75 Nucleus 
1195 Q13283 Ras GTPase-activating protein-binding protein 1 G3BP1 156 30 52,164 5.36 0.042 0.74 Nucleus 
23 P08865 40S ribosomal protein SA RPSA 354 59 32,854 4.79 0.001 0.73 Cytoplasm, nucleus 
296 P31930 Cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 323 37 52,646 5.43 0.021 0.72 Mitochondrial inner membrane 
952 Q0QEN7 ATP synthase subunit beta ATP5B 475 55 48,113 4.95 0.021 0.69 Mitochondrial inner membrane 
1623 P40926 Malate dehydrogenase MDH2  159 45 35,503 8.54 0.017 0.69 Mitochondrial inner membrane 
682 P26641 Elongation factor 1-gamma EEF1G 255 26 50,119 6.27 0.022 0.68 Cytosol 
1867 Q9Y3D9 28S ribosomal protein S23, mitochondrial MRPS23 97 36 21,711 8.94 0.017 0.67 Mitochondrion 
15 Q9ULV4 Coronin-1C CORO1C 108 12 53,249 6.65 0.002 0.66 Actin cytoskeleton 
1549 P06748 Nucleophosmin NPM1 140 40 32,575 4.64 0.027 0.66 Nucleus 
574 P09874 Poly [ADP-ribose] polymerase 1 PARP1 327 34 113,084 8.99 0.008 0.66 Nucleus 
1810 P19388 
DNA-directed RNA polymerases I, II, and III subunit 
RPABC1 
POLR2E 109 31 24,551 5.69 0.032 0.65 Nucleus 
1625 P29692 Elongation factor 1-delta EEF1D 387 50 31,122 4.90 0.008 0.64 Cytosol 
1387 Q16576 Histone-binding protein RBBP7 RBBP7 144 21 47820 4.89 0.028 0.61 Nucleus 
1358 Q12849 G-rich sequence factor 1 GRSF1 220 28 53,126 5.83 0.012 0.60 Cytoplasm 
704 Q3B7T1 Erythroid differentiation-related factor 1 EDRF1 107 53 138,528 5.93 0.036 0.60 Nucleus 
27 P35527 Keratin, type I cytoskeletal 9 KRT9 90 35 62,064 5.14 0.040 0.59 Intermediate filament 
175 P13693 Translationally-controlled tumor protein TPT1 201 45 19,595 4.84 0.011 0.59 Cytoplasm 
695 Q01518 Adenylyl cyclase-associated protein 1 CAP1 68 12 51,855 8.29 0.013 0.57 Cell membrane 
1203 P62937 Peptidyl-prolyl cis-trans isomerase A PPIA 278 50 18,012 7.82 0.020 0.56 Cytoplasm, nucleus 
695 Q96IZ6 Methyltransferase-like protein 2A METTL2A 78 18 43,521 5.69 0.018 0.56 Nucleus 
14 Q86VI3 Ras GTPase-activating-like protein IQGAP3 IQGAP3 80 18 184,699 7.34 0.005 0.52 Intracellular 
1794 Q07021 
Complement component 1 Q subcomponent-binding 
protein, mitochondrial 
C1QBP 242 26 31,362 4.32 0.035 0.48 Mitochondrion 
337 P35232 Prohibitin PHB 690 66 29,804 5.57 0.026 0.46 Mitochondrial inner 
29 
 
membrane, nucleoplasm 
37 P27348 14-3-3 protein theta YWHAQ 123 29 27,764 4.68 0.000 0.42 Cytoplasm, nucleus 
39 Q969G3 
SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily E member 1 
SMARCE1 89 20 46,649 4.85 0.000 0.42 Nucleus 
39 P62258 14-3-3 protein epsilon YWHAE 136 43 29,174 4.63 0.000 0.42 Cytoplasm 
34 P61981 14-3-3 protein gamma YWHAG 75 21 28,303 4.80 0.000 0.41 Cytoplasm 
52 P05387 60S acidic ribosomal protein P2 RPLP2 122 64 11,665 4.42 0.007 0.41 
Cytosolic large ribosomal 
subunit 
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Table 2. Proteins identified by both, proteomic and transcriptomic, studies as differentially-expressed in 1,25(OH)2D3- vs vehicle-treated SW480-ADH cells 
 
PROTEIN 
PROTEOMIC TRANSCRIPTOMIC 
FOLD 1,25(OH)2D3 FOLD 1,25(OH)2D3 
CHANGE TREATMENT (h) CHANGE TREATMENT (h) 
RBBP4 0.78  8 0.50  4 
   0.43 48 
PKM2 0.78  8 0.14 48 
SMARCE1 0.78  8 0.43  4 
 0.42 48   
ATP5A1 0.56  8 0.33 48 
SNRPA1 0.41  8 0.31 48 
ACTB 1.72 48 2.83 48 
RDX 1.63 48 2.14 48 
EZR 1.61 48 2.46 48 
VCL 1.55 48 2.83 48 
SFPQ 0.75 48 0.38 48 
POLR2E 0.65 48 0.33 48 
EEF1D 0.64 48 0.50 48 
YWHAE 0.42 48 0.38 48 
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FIGURE LEGENDS 
Figure 1. (A) Western blot analysis showing the expression of markers in nuclear (N; 
HDAC, Lamin B and VDR) and cytosolic (C; -Tubulin and Rho-GDI) extracts of 
SW480-ADH cells treated with 1,25(OH)2D3 or vehicle for the indicated times. Data 
from three independent experiments (Exp.) are shown. (B) Representative 2D map 
obtained by 2D-DIGE analysis of nuclear proteins from SW480-ADH cells treated 
with 1,25(OH)2D3 or vehicle for 48 h. Nuclear extracts from SW480-ADH cells treated 
with 1,25(OH)2D3 or vehicle for 48 h were differentially labeled with Cy5 and Cy3 dyes. 
An internal standard, combining proteins from both extracts, was included in all gels after 
labeling with Cy2 dye. Samples were separated in 3-10 NL IPG strips for IEF and standard 
SDS-PAGE for the second dimension. The representative spot map corresponds to the 
internal standard, which is common to all gels analyzed, at 48h. Only those spots whose 
levels of expression were significantly different between both conditions (ANOVA 
p<0.05; fold-change <0.80 or >1.25) were considered for the analysis. Those proteins that 
were unequivocally identified by MALDI-TOF-TOF analysis are named and indicated by 
arrows (black: overexpressed proteins; white: repressed proteins). 
 
Figure 2. Validation of 1,25(OH)2D3 target proteins in SW480-ADH cells by Western 
blot analysis. Representative Western blots showing the expression of several proteins 
identified by 2D-DIGE. Nuclear extracts from SW480-ADH cells treated with 
1,25(OH)2D3 or vehicle for 8 h (RBBP4) or 48 h (all others). Numbers are fold-change 
values after normalization using LMNB as control. Experiments were performed in 
triplicate using extracts from three independent assays. The volume density of the 
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experiments and the standard deviation was calculated and represented in bar graphs. 
Statistical significance was assessed by two-tailed unpaired Student’s t-test (* p<0.05, ** 
p<0.01. 
 
Figure 3. Quantitative RT-PCR analysis of the RNA expression corresponding to the 
proteins regulated by 1,25(OH)2D3 in SW480-ADH cells. 
Quantitative RT-PCR study of KHSRP, PARP1, SMARCE1 and SFPQ in 1,25(OH)2D3- or 
vehicle-treated SW480-ADH cells at 48h. 18S rRNA expression was used for 
normalization. CDH1/E-cadherin was included as a positive control. Statistical 
significance was assessed by two-tailed unpaired Student’s t-test (* p<0.05, ** p<0.01,*** 
p<0.001. 
 
Figure 4. Subcellular distribution of several target proteins in SW480-ADH cells 
treated with 1,25(OH)2D3 or vehicle. Representative immunofluorescence and confocal 
microscopy images showing the expression of the target proteins in SW480-ADH cells 
treated with 1,25(OH)2D3 or vehicle for 48 h. Nuclei were counterstained with DAPI. 
Confocal microscopy was performed with a TCS SP5 laser scanning microscope (Leica). 
Bars, 25 µm. 
 
Figure 5. Protein classification according to localization and biological function. 
Functional annotation of the identified proteins was carried out with DAVID, a web-
accessible tool. A. Pie chart indicating the number of identified proteins involved in each 
molecular function. Gene ontology numbers are provided. EF: Enrichment scores for each 
term. B. Gene-term 2D heat map view for functional annotation clustering of the identified 
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proteins involved in RNA processing and binding. Green box. Corresponding gene-term 
association positively reported. Black box. Corresponding gene-term association not 
reported yet.  
 
Figure 6. 1,25(OH)2D3 treatment of colon cancer cells regulates spliceosome and cell-
adhesion proteins.  In silico protein interaction analysis for the proteins identified in 
1,25(OH)2D3-treated SW480-ADH cells was performed using STRING (Search Tool for 
the Retrieval of Interacting Genes/Proteins). STRING was required to add 10 more 
predicted functional partners to facilitate the creation of networks. These proteins are 
indicated by red boxes. Most of the added proteins were members of the RNA Polymerase 
II complex. Two functional sets of proteins were highlighted manually with circles: 
proteins involved in gene expression regulation and RNA processing, which are related to 
the spliceosome (yellow circle), and those involved in cell-cell and cell-matrix interactions 
in relation to the cytoskeleton (green circle). Different line colors indicate different types 
of evidence for the association: Neighborhood (green), co-expression (dark blue), 
experimental (red), association in curated databases (blue) or co-mentioned in PubMed 
abstracts (light green).  
 
